FIELD: biotechnology.
SUBSTANCE: method for the treatment of a disease with increased CD38 expression in an individual is proposed. The method includes subcutaneous injection to the individual of a standard dosage form of an isolated human anti-CD38 antibody, where the standard dosage form is in a volume of 3 ml or less at a dose from 0.03 to 0.6 mg per 1 kg of the body weight.
EFFECT: invention provides effective therapy of autoimmune and cancer diseases with low doses and volumes of anti-CD38 antibodies, preventing side effects and inconveniences related to injection of high doses of preparations for systemic therapy with anti-CD38 antibodies.
15 cl, 108 dwg, 15 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBCUTANEOUS DOSING OF ANTI-CD38 ANTIBODIES | 2019 |
|
RU2810953C2 |
| METHODS AND MATERIALS FOR ASSESSMENT OF RESPONSE TO THERAPY AGAINST PLASMA-BLASTS AND PLASMA CELLS | 2017 |
|
RU2787629C2 |
| BISPECIFIC ANTIGEN-BINDING PROTEIN EGFR/CD16 | 2019 |
|
RU2792240C2 |
| BINDING MOLECULES SPECIFIC TO IL-21 AND THEIR USE | 2015 |
|
RU2804456C1 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
| ANTIBODIES TO PROTEIN CD38, AND THEIR USE | 2019 |
|
RU2776795C2 |
| STABLE MULTI-SPECIFIC ANTIBODIES | 2018 |
|
RU2779602C2 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
| ANTIBODIES AGAINST CXCR5, THEIR COMPOSITIONS AND USE | 2018 |
|
RU2798422C2 |
